Advances in Primary Biliary Cholangitis: Real-World Therapeutics, Biomarkers, and Patient-Centered Outcomes
Nov
2026
World Class Speakers
Description
This session reviews real-world and trial data on PBC therapeutics — including elafibranor, seladelpar, and linerixibat — alongside emerging biomarkers and digital tools for tracking pruritus and disease activity.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 1B
Elafibranor Versus Seladelpar in UDCA-Treated Primary Biliary Cholangitis: A 111-Health-System Propensity-Matched Comparative Effectiveness Study
Cynthia Levy, MD, FAASLD | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 1B
Real-World Efficacy of Elafibranor in patients with Primary Biliary Cholangitis: Experience from a community-based hepatology practice
Cynthia Levy, MD, FAASLD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - Bluebird Ballroom 1B
First-in-disease objective assessment of scratch and sleep patterns using a wearable digital health tool in primary biliary cholangitis: The LUMINARIA study
Cynthia Levy, MD, FAASLD | Abstract Presenter
